Is there any generic drug of ponatinib on the market and the quality and price comparison of generic drugs

Ponatinib is an oral third-generation tyrosine kinase inhibitor, mainly used to treat patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is especially suitable for patients who are resistant or intolerant to other tyrosine kinase inhibitors. Because it has shown significant efficacy against drug-resistant mutant strains (such as T315I mutation) in clinical practice, it has attracted much attention. However, ponatinib has not yet been officially launched in China, so domestic patients are temporarily unable to purchase the original drug through formal channels, and its price and medical insurance coverage are not yet clear.

In overseas markets, the original drug of ponatinib is mainly the Hong Kong version, with each box selling for about more than 30,000 yuan. The ingredients, dosage and production process of the original drugs are strictly controlled in accordance with international standards. The clinical efficacy and safety are fully supported by data and are suitable for patients who have high requirements for drug quality. However, the high price has also become an important factor limiting long-term use by patients, especially for patients with chronic leukemia who require long-term maintenance treatment.

In order to reduce the cost of medication, generic drugs of ponatinib have also appeared in overseas markets, including the Lao version and the Bangladeshi version. The price of the Lao version of the generic version of ponatinib is about more than 700 yuan, while the price of the Bangladeshi version of the generic drug is about more than 1,000 yuan. Compared with original drugs, generic drugs have significant price advantages, significantly reducing the financial burden on patients. At the same time, the pharmaceutical ingredients of these generic drugs are basically the same as those of the original drugs and can provide similar anti-leukemia effects, but there may be certain differences in production processes, excipients and registration standards.

Generally speaking, the original drug and generic drug of ponatinib are generally similar in ingredients and clinical efficacy, but the price difference is significant. The original drug has reliable efficacy and sufficient data, but is expensive; the Lao and Bangladeshi versions of generic drugs are affordable and provide viable alternatives for patients who cannot afford the high price of the original drug. When choosing to use the drug, patients need to pay attention to the source and authenticity of the drug, and ensure that it is obtained through formal channels to ensure the safety and efficacy of the drug. At the same time, the dosage and medication regimen should be reasonably adjusted under the guidance of a professional doctor.

Reference link:https://www.drugs.com